Clinical trial · Interventional
Effect of Sitagliptin on Polycystic Ovarian Syndrome Patients
Effect of Sitagliptin on Clinical, Metabolic and Hormonal Parameters in Polycystic Ovarian Syndrome Patients
NCT05972928CI-TRIAL-00124919completedPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Study aims to determine the proposed positive influence of Sitagliptin in manipulating hormonal , metabolic and inflammatory parameters in the treatment of Polycystic ovary syndrome and subsequent infertility
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sitagliptin 100mg | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Sitagliptin
- description
- Sitagliptin at a dose of 100 mg every 24 hours for 3 months
- interventionNames
- Drug: Sitagliptin 100mg
- type
- NO_INTERVENTION
- label
- control
- description
- patient won't receive medication
Primary outcomes (1)
- measure
- Body weight loss in Kilograms
- timeFrame
- 3 months
- description
- Body weight before - Body weight after
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: polycystic ovary syndrome usually diagnosed based on the Rotterdam criteria if 2 of 3 criteria are present: 1. oligo- and/or anovulation 2. hyperandrogenism (HA) (clinical and/or biochemical) 3. polycystic ovary morphology (PCOM) on ultrasonography (either 12 or more follicles measuring 2-9 mm in diameter and/or an increased ovarian volume \>10 cm3). Exclusion Criteria: 1. congenital adrenal hyperplasia 2. Brittle control of a thyroid disorder 3. Diabetic on Metformin or any another antidiabetic drugs affecting insulin resistance 4. chronic kidney disease 5. liver dysfunction 6. documented use of oral hormonal contraceptives and hormone-releasing implants in the past 6 months prior to study entry 7.Lipid lowering Consumption
References
Publications (0)
Data not yet available
No reference posted for this study.